Abstract:The tumor microenvironment (TME) is crucial in cancer development and therapeutic response. Immunotherapy is increasingly recognized as a critical component of cancer treatment. While immunotherapies have shown efficacy in various cancers, including breast cancer, patient responses vary widely. Some patients receive significant benefits, while others experience minimal or no improvement. This disparity underscores the complexity and diversity of the immune system. In this study, we investigated the immune landscape and cell–cell communication within the TME of breast cancer through integrated analysis of bulk and single-cell RNA sequencing data. We established profiles of tumor immune infiltration that span across a broad spectrum of adaptive and innate immune cells. Our clustering analysis of immune infiltration identified three distinct patient groups: high T cell abundance, moderate infiltration, and low infiltration. Patients with low immune infiltration exhibited the poorest survival rates, while those in the moderate infiltration group showed better outcomes than those with high T cell abundance. Moreover, the high cell abundance group was associated with a greater tumor burden and higher rates of TP53 mutations, whereas the moderate infiltration group was characterized by a lower tumor burden and elevated PIK3CA mutations. Analysis of an independent single-cell RNA-seq breast cancer dataset confirmed the presence of similar infiltration patterns. Further investigation into ligand–receptor interactions within the TME unveiled significant variations in cell–cell communication patterns among these groups. Notably, we found that the signaling pathways SPP1 and EGF were exclusively active in the low immune infiltration group, suggesting their involvement in immune suppression. This work comprehensively characterizes the composition and dynamic interplay in the breast cancer TME. Our findings reveal associations between the extent of immune infiltration and clinical outcomes, providing valuable prognostic information for patient stratification. The unique mutations and signaling pathways associated with different patient groups offer insights into the mechanisms underlying diverse tumor immune infiltration and the formation of an immunosuppressive tumor microenvironment.

Microvascular blood flow in the airway mucosa modulates bronchoconstriction.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

Breast cancer immune microenvironment: from pre-clinical models to clinical therapies

Intracranial hemorrhage at the onset of thrombotic thrombocytopenic purpura in an infant: therapeutic approach and intensive care management.

Modelling the tumor immune microenvironment for precision immunotherapy

Exploring T Lymphocytes, Myeloid-Derived Suppressor Cells, and Tumor-Associated Macrophages in the Breast Cancer Microenvironment

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Managing the TME to improve the efficacy of cancer therapy

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Understanding the tumor immune microenvironment (TIME) for effective therapy

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy

New horizons in tumor microenvironment biology: challenges and opportunities

The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies

Towards targeting the breast cancer immune microenvironment